Relay Therapeutics, Inc Investor Event Transcript, Nov 10, 2026
Relay Therapeutics, Inc. (RLAY)
Relay will present ASH data on all 32 patients from its dose randomization portion, after showing a 60% volumetric response rate across three doses at ISFA in May. Management models five and a half months of median PFS for CAPI. Pfizer supplies termociclib under a clinical trial supply agreement for a frontline trial due to start early next year. AI summary
Conference Transcript - RLAY 2026-11-10
Devjit, Analyst — Guggenheim
All right, good afternoon. Saving the best for the last year, and thank you for joining. This is Devjit from Guggenheim Therapeutics team, and thank you all for joining our third annual Healthcare Innovations Conference. My privilege to welcome Sanjeev Patel. President and CEO of Relay Therapeutics, and joining Sanjeev are Don Bergstrom, President of R&D, and Peter Amar, Chief Corporate Development Officer. Thank you all.
Sanjeev Patel, CEO
Thank you, Devjit, for the invite. It's a pleasure to be here.
Devjit, Analyst — Guggenheim
I do not want to insult your intelligence by asking you to do an intro. So why don't we just get straight to the Q&A? Happy to do an intro. No, I think. Anybody on this, you know, anybody listening in probably knows enough about Relate, so let's skip the intro because there is a lot happening with the company.
Donald Bergstrom, Other
Yeah.
Devjit, Analyst — Guggenheim
So I want to start on the ASH update. Yeah. Let's talk about the data first. We are expecting somewhere in the ballpark of 60 patients. Is that sort of a right estimate?
Sanjeev Patel, CEO
I think at the moment, all we're saying is that the ISFA data that we showed back in May of this year, we showed data on the 32 patients in the dose randomization portion. Of those 32 patients, we showed safety data on all 32, and we showed efficacy data on 20, and that was because 12 of those patients hadn't yet had a scan at the data cut. At ASH, what we'll show is those 32 patients again, and we'll show now efficacy and safety data on all 32 patients. And as you may remember, back in ISFA, we showed across those three doses a 60% volumetric response rate. And so I think, you know, the questions for investors is how has that evolved as we go from this end of 20 to 32? Our hope is that it stays in and around that and that we can show some consistency to make sure that, you know, investors understand how differentiated our therapy is. And obviously looking at the much longer follow-up on that, how the safety profile evolves, we'd obviously want it to stay consistent to what we saw earlier in the year. And then we'll show additional data from the dose expansion portion of the trial. There, the majority of the patients that we've enrolled in those dose escalation cohorts have been at the 400 milligrams once a day. And so, you know, we're not going to say today, you know, how many patients will show there, but those patients will predominantly have had only one scan. So, you know, the efficacy value of patients will only be at the 12 weeks. And the goal there is to show two things. Once we want to show a very tolerable profile. As we, you know, came out of ISVA, the real predominant feedback from the community of treating physicians is tolerability is key. The volumetric response rate is interesting for the FDA, but what patients want is a tolerable therapy they can take for life. And so the focus of us in this, you know, choosing the dose to go forward with in the pivotal trial is going to be, what is a dose that a patient can take forever? And so what we want to show is low levels of hypoglycemia, diarrhea, rash, stomatitis. And obviously the efficacy profile has to be differentiated, so it has to clear the bar of valpalosib in the kind of high 20s. And so as long as we can do that with a tolerable safety profile, I think investors should feel very confident that we'll produce a differentiated therapy that should be commercially successful. So that's what we look forward to at ASH on the data. We'll also show a regulatory update. So the path forward there around, you know, what is the indication statement and what's the pathway towards accelerated approval, we'll provide color on at ASH as well. So kind of lots to think about as we go forward, but that's kind of the overview of what we hope to show.
Devjit, Analyst — Guggenheim
Got it. So, on the regulatory side, at this point, I'm assuming the meeting has already happened or about to happen? We're not commenting. Got it. Do you expect to have, or are you hoping for a broad label right off the bat? From a filing perspective.
Sanjeev Patel, CEO
Yeah, look, there's a precedent being set here by Novartis where they have a label for probes, and they got an accelerated approval, and then they're running now a separate trial for lymphatic malformations. So the precedent is out there of having separate labels and separate indications and separate trials. Our approach will be to obviously go for the broad pooled population of having pros and LMs together, And obviously, that is a question for the FDA to see. Our logic is that, you know, we believe both these conditions are predominantly caused by a PI3K-alpha mutation, and so there is some commonality in this group. You do not need to test these patients, and so we'll try and go for a broad label. But I think we'd be happy with the base case that we have of having, exactly as Novartis has, you know, two separate labels and two separate trials.
Devjit, Analyst — Guggenheim
So from the FDA perspective, what would prevent them from going forward with APROS plus LM? You might have enough patients, you know, and the safety is probably going to look far better than what the commercially approved drug is. So what's the hold up there?
Donald Bergstrom, Other
I think all you're hearing from us is that there's not a lot of precedence in this space. And so we don't want to get out over our skis on trying to predict what the FDA may or may not do in a context, in a disease context, in which we can't point you to six to seven, a dozen different instances of precedent to support our hypothesis of what to do or not to do. So far in our data, the performance of Zovega and LMs and PROS has been extremely consistent. We do think the underlying disease biology is very similar. A lot of the morbidities that exist with these patients is very similar. The treatments that you see these patients are on before they come on to Zovega, very similar. Sclerotherapy, surgery, serilinus, or a polysib. There's a lot of good scientific justification and rationale as to why you can pull these patients together, but that's ultimately going to be a decision for the agency to apply now.
Devjit, Analyst — Guggenheim
Got it. Thinking about the efficacy data, although you'll have, you know, just 12 weeks of follow-up, is there a bar? Because the reason this comes up a lot is there is a bunch of copycats, you know, coming through quickly. If the label doesn't get expanded or if the efficacy is, let's say, fall short of expectations, that opens up an avenue for these copycats. You know, your take on those?
Sanjeev Patel, CEO
I mean, I think, as we've said, look, we believe that the... The bar really here is around safety and tolerability. That's what people want. They want a tolerable therapy that they can take for life. And as long as it clears the bar of alpalosib, which is the currently available therapy, it will be commercially successful. And so that's really our approach to this. Obviously, you know, we'd like it to be differentiated from alpalosib. We've shown already that we can achieve 100% response rate with the 300 milligram once a day dose. They won't stay at 100% as you get more patients. So we've shown that you can really max out the efficacy. The real question is, should you? And so you could take your approach around, like, you don't want to have any kind of competitive challenge in the future, so just max out the efficacy. That will actually result in a commercially unsuccessful therapy. You could actually see that with Alpalacib, right, which is they have a therapy which they really try to max out the efficacy with their 250 milligram dose, which is not tolerable. And so patients cycle on it and then they cycle off it, commercially unsuccessful. So I think for us, the choice is around threading the needle between having enough efficacy to, you know, make sure that we remain differentiated, but it really is around the safety and tolerability profile that it's important. The second point around, yes, we imagine that there'll be entrants that come behind us with PI3K mutant selective assets. It's not so easy to enter this field as a fast follower for lots of different reasons. You know, the reason that these patients and physicians are very cautious, and so the thing that made us, you know, able to recruit the patients we did in the time frame we did was the several hundred patients that we have over multiple years now from breast cancer. And again, that took us four years to accumulate, the chronic tox that we have. And obviously, the sites that are out there, there aren't that many sites across the world where these trials can be conducted. And obviously, we have a very robust site footprint now. And many of these sites can only run a small number of trials at any one time. So I think that coming after us is going to be tough. And so rather than us try to, you know, maximize the response rate to try and shut the door, I think the best way to shut the door is to use a commercially very attractive profile that physicians want to use and patients get comfortable with. And so that's our approach to choosing the dose. Got it.
Devjit, Analyst — Guggenheim
So on the commercial side then, I mean, you are at the cusp of getting some FDA feedback, so it's almost time to talk commercial. Where do you think these patients are? I mean, from a percentage basis, are, you know, located at vascular centers, pediatricians, dermatologists? How should we think about the market?
Donald Bergstrom, Other
First thing to say is this is a very nascent disease space, and so the direct answer to your question is no one really knows. As we now have dozens of sites across U.S., Europe, and Australia, we've been out seeing in person all the leaders of the multidisciplinary teams at all those sites over the past three or four months. So as we see the landscape and have done the work that we can do either through primary market research, talking to our investigators and or what's in the academic literature, it looks like a lot of the moderate to severe patients who are seeking more complex treatment, you know, serial surgeries or serial sclerotherapy embolization or contemplating the, you know, the one of the two systemic therapies available, Well, they do find their way to the vascular anomaly centers, where you have this multidisciplinary team that can treat the totality of the disease for the patients. And so we think there's a few dozen of those in the U.S. and probably a few dozen of them in Europe. And so between that number of centers, you're probably capturing a large portion today of the known addressable market. Now, do patients originate in some of the primary care areas and or dermatology and other disciplines? Absolutely, but I think as they progress towards contemplating systemic therapy, they are generally making their way to the vascular anomaly centers today.
Devjit, Analyst — Guggenheim
Got it. So, closing this regulatory discussion here, Thank you very much. Obviously, PROS plus LM debate, and then the scope of the label in terms of adolescence versus pediatrics. Can you sort of give us a sense of how many of these 12 and under patients are diagnosed and known versus adults? If the label was just an adolescence versus an adult's, what happens to these younger patients and how many are there?
Donald Bergstrom, Other
So I don't think there's a disparity between the diagnosed and known. Across adolescents or adults. There are gaps in adult care, so a patient that was diagnosed as an adolescent or pediatric, you know, most of these vascular anomaly centers are at children's hospitals, and so some of them will age out of the children's hospital care and then, you know, aren't cleanly passed off to adult hemontics and may get lost in the system a little bit today. That is a known problem, something we pay close attention to and have a lot of conversations about how do you fix in the future. But specifically to your question, it's not a diagnosis problem. It's really a continuum of care problem that is readily acknowledged across all professionals in the space, and there's a lot of activity and effort to go against solving that problem.
Devjit, Analyst — Guggenheim
So what I'm hearing for a lifelong therapy, it's going to be safety, safety, safety first. And if you were to rank order glycemic issues. Rash, diarrhea, which ones are the most important for patients to stay on therapy?
Donald Bergstrom, Other
Yeah, in any context, these patients come on with morbidity of their disease, and the reason why safety and tolerability is so important is because as that gets too severe, that then becomes the other side of that morbidity coin, which is really hampering their quality of life, which is really what we're ultimately trying to talk about, is symptomatic improvement and quality of life improvement. If that comes with volumetric reduction, that's secondary to these patients and physicians. And so, you know, it's the totality of the safety profile, the severity of any one event. So I think one of the things we will focus a lot on is minimizing the number of grade three AEs in totality overall. And then the other thing we're going to be watching for is, are these events happening Is it happening iteratively over a longer duration of treatment? Or do they happen earlier in the cycle one or cycle two? Are they largely self-resolving? Can they be easily managed? And do you see them dissipating over time? Those are the concepts that we'll be looking for from a safety and tolerability standpoint.
Devjit, Analyst — Guggenheim
Got it. We could go on with this, but given the scope of the pipeline here, let's switch to the second-line breast cancer study. So the rediscovered is going to enroll sometime. Before the first half of next year, or around the first half of next year. So the office conversation now has become, how should we model it? What's the most reasonable expectation for CAPI? And given one of the sponsors recently had a significant compression in their PFS, how should we think about where, so are you guys going to line up?
Sanjeev Patel, CEO
Yeah, so I think on the CABY-Visertib, you know, there's enough data out there now that makes us confident to model five and a half months. And that's what we're seeing both in the kind of sub cuts we saw in the pivotal trial as well as the real-world evidence. I think in terms of, you know, how you model Zorvega, obviously we've shown 11 months' worth of PFS in the data that we presented, but that was in a kind of mixed second, third-line population. And so on one side you see potentially, you know, as we go to, you know, 200 sites across the world that investigators are less familiar with using Zorvega, that you could see a compression. On the other side, it's balanced by the fact that you have now a pure second-line patient population. So we do think the two things will probably balance them out, so we feel confident that we'll end up back where we started. That gives us a significant buffer against the five and a half months, and so we expect a high confidence of a positive trial.
Devjit, Analyst — Guggenheim
And in case of a compression, how much are you sort of, how much compression have you modeled in from a staff's perspective?
Donald Bergstrom, Other
We haven't disclosed that, but suffice to say Okay, the two barometers here obviously are... You know, our 10.5 to 11 months median PFS that we've seen across our two independent phase one single arm experiences, and then on the CAPI side, as Sanji said, a couple of different subcuts of CAPI, Capitella 291, both land you at about five and a half months of median PFS for CAPI. You can imagine, as we designed the study, we did it with some conservatism on both sides, anticipating the possibility for some compression for Zovega and maybe Maybe even a little bit of over-performance of CAPI and still have a buffer to have a successful study.
Devjit, Analyst — Guggenheim
Got it. And, you know, your sponsor, the other sponsor will have Geta in the market. At some point, middle of next year, how does that change your launch assumptions, or it's completely independent, given that yours is an oral versus an infusion product, and with a little bit of a safety package, or more than a little bit of a safety package?
Sanjeev Patel, CEO
Yeah, I mean, I think the assumptions that are probably now, now we know the get-a-date are much more kind of robust and positive than when we didn't know. And so, obviously, we did a lot of thinking around, you know, the scenarios of what... What a getatolosive triplet could look like, and a lot of market research, and obviously it's a weekly IV regimen that comes with prophylactic steroid mouthwash and potentially other prophylactic measures, so it's a multi-drug regimen that, you know, requires a patient to come to an IV infusion center once a week. And so... The real challenge for us commercially is it's going to be on the market before us, and so for it to really establish a dominant position, our modeling was that it has to show a significant benefit over an aural that, you know, is in the 10-11 month range, and so it had to show. Over 15 months of PFS, if not, you know, closer to 18 months to be really difficult to dislodge. And so those were our kind of most pessimistic assumptions, which is if it did show 18 months of PFS in this space, even though it had all these constraints, it would be a difficult commercial proposition to go up against. And so now we know the answer is 11 months. I think we feel much more confident that as we launch into this market, irrespective of if they've got a head start with multiple years that this should be a market that we could take share from rapidly.
Donald Bergstrom, Other
There's an interesting analog here when you look at Alpelisib and Cappy Veserta. Alpelisib was launched in 2019. Cappy launched in... Late 2024, and you had the context there was actually CAPI numerically had a slightly less median PFS in its registrational studies compared to by leave at that time. It just had the perception of a better tolerability profile, really probably just a trading of some toxicities for other toxicities. And at that time, you had alpalosib had plateaued at about $350, $400 million a year run rate. And within six months, or sorry, six quarters, CAPI had completely taken that market share and grown the market. That's in the context of slightly worse PFS in a trading of toxicities. Here, our proposition is going to likely be if our phase one, two data play out, and I recapitulate and rediscover two, you'll have probably similar, If not slightly better, medium PFS and a dramatically better safety and tolerability profile, and that's before you even get into the convenience of an oral regimen versus a weekly IV.
Devjit, Analyst — Guggenheim
You're 12, well, 10 months roughly from the time that our study enrolls to where we could get the data. Obviously, it's time to almost start building your commercial organization. How are you thinking about the scope and size of that as you prepare for launch?
Sanjeev Patel, CEO
Yeah, it's definitely on our mind now. We announced last week a head of commercial, Shannon Campbell. She was the ex-U.S. head for Novartis Oncology. She was there when, you know, they were with Ribocyclib there for the launch of Alpalosib, both in breast cancer and vascular anomalies. So she knows both breast cancer and vascular anomalies markets very well, and I think, you know, she'll get to work now on, you know, doing all the preparation and sizing that we need. The breast cancer market is very well established, and so we know from, you know, many companies of our size and scale, you know, how they have invested and sized their sales forces. So I think there's a lot of knowns on the breast cancer side. I think the unknowns for us are just going to be how we think about this kind of total greenfield of vascular anomalies and how to do a lot of work that no other companies have ever done. So in breast cancer, there's plenty of companies that have laid the groundwork for lots of medical education, patient advocacy, that, you know, that all that work needs to be done on the vascular anomaly side. And so we will do all the work that is needed to make sure that we do the best job we can as we launch Zerbega.
Devjit, Analyst — Guggenheim
Let's switch to the front line because we can go on with this, but limited time here. There's been a lot of noise around the new Pfizer P3K. You know, when we looked at it structurally, it doesn't look any different than some of the prior non-viable candidates, if I might call it. Thoughts as to why Pfizer might even move this into the clinic?
Donald Bergstrom, Other
Look, they are a breast cancer company, and they currently do not own a PI3K inhibitor today. So we've known, you know, Geditolisib came from Pfizer. We've known that they have active research against the target. I'm sure they still have active research against the target. So it is not surprising to us that they are trying to find a pretty low-cost way to have some presence in their pipeline with a PI3K alpha inhibitor. Today, it has no bearings on what we're doing. We have a clinical trial supply agreement in place with Pfizer where they supply a termociclib, their selective CDK4 molecule, for our frontline trial that we're on track to start early next year, and they've been absolutely great to work with in that context, and we remain operationally on track to move as fast as we can, and they are supporting that without question. So that's all we care about at this point.
Peter Amar, Other
We agree with your assessment of the molecule.
Donald Bergstrom, Other
We've seen a lot of these come through. I'm sure we'll see more try, but we are very confident in the bar that we are setting to maintain our commercial superiority for a very long period of time.
Devjit, Analyst — Guggenheim
And when you think about your frontline study, is 20 months the right kind of PFS for the control arm? Or it could be slower because patients don't, or mutant PI3K kinase patients don't respond to CDK4-6 as well in the frontline setting?
Peter Amar, Other
That's exactly been the experience, that the PIK3CA mutant patients do benefit from CDK4-6 inhibitors, but not to the same extent as PIK3CA wild-type patients. So what we've seen in the case of ribocyclob in the Mona Lisa trial in endocrine-sensitive patients was while the blended population overall was 28 months, the PIK3CA mutant population was 19 and a half months, and the PIK3CA wild-type population was over 31 months. There's about more than a year difference. So we feel comfortable with this 20-month, you know, with the 20-month assumption roughly in the PIK3CA mutant population based on some of these retrospective analyses from the CDK4-6 inhibitors.
Devjit, Analyst — Guggenheim
And the dose selection, this comes up a lot in the discussions because, you know, you're going forward with the 150, but the way I think about it, it does give you the flexibility to go down to 100 for a, you know, a triplet that's going to be used for almost three years. Is that the right way to think about it? Because even with the 100 meg, you have enough target coverage?
Peter Amar, Other
Yeah, exactly. And just to remind you, because a termocyclob does increase the blood concentration of Zovega, that 150 milligram dose gives us approximately the same target coverage as our 400 milligram dose in the doublet with Fulvestrin. So we're essentially using full dose Zovega, even though the actual dose the patient's taking is lower.
Devjit, Analyst — Guggenheim
Got it. Unfortunately, we kind of run the clock here. I'm really looking forward to the ASH update across the board and then take it from there. It's gonna be an interesting, you know. Three, four years for you guys. Great.
Sanjeev Patel, CEO
Well, thanks again, Devjit, for the invitation.
Devjit, Analyst — Guggenheim
Thanks to Guggenheim. Appreciate the time. Thank you so much.
Peter Amar, Other
Thank you.